Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM6A | O15550 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 10/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9351927 | 0.84 | KDM4E (0.57) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL9518157 | 0.83 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL6949699 | 0.80 | KDM4E (0.53) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL9387565 | 0.79 | KDM4E (0.51) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL9700134 | 0.79 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL25529223 | 0.79 | SMN1; SMN2 (0.35) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL30669321 | 0.78 | KDM4E (0.51) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL30669381 | 0.78 | KDM4E (0.51) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5525055 | 0.78 | KDM4E (0.62) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL10480777 | 0.78 | PKM (0.54) | KDM4ETP53CYP2D6HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | APOTEX TECHNOLOGIES INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | APOTEX TECHNOLOGIES INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | APOTEX TECHNOLOGIES INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-9550733-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9073865-B2 | Fluorinated derivates of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2015-07-07 | — | — | US | disclosed |
| US-9073865-B2 | Fluorinated derivates of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2015-07-07 | — | — | US | disclosed |
| US-9073865-B2 | Fluorinated derivates of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2015-07-07 | — | — | US | disclosed |
| EP-2448922-B1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC (CA) | 2014-08-20 | — | — | EP | disclosed |
| EP-2448922-B1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC (CA) | 2014-08-20 | — | — | EP | disclosed |
| CN-102712591-B | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC | 2014-06-25 | — | — | CN | disclosed |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| WO-2011000104-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | FH, FECH, FTH1 | KDM4E 3133/4885TP53 869/4885CYP2D6 311/4885 |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | FH, FECH, FPGS | KDM4E 2785/4885TP53 1007/4885CYP2D6 436/4885 |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | FH, FECH, FPGS | KDM4E 2376/4885TP53 1069/4885CYP2D6 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.